PRLog - Oct. 26, 2012 - SAN DIEGO -- SAN DIEGO ---Kalos Therapeutics, Inc. Kalos Therapeutics, Inc. is a biomedical company targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation)
Co-Founder Kalos Therapeutics, Inc.
Kalos Therapeutics is one of 22 companies accepted into the program in the Life Sciences category out of a pool of about 50 applicants. The Life Sciences category focuses on companies specializing in instrumentation, diagnostics, bio-markers, microbiology, molecular biology, therapeutics, pharmaceuticals and other life sciences specialties.
George Colberg Co-founder of Kalos Therapeutics, Inc., commented, “Working with CONNECT is a wonderful opportunity for a Company to get investor ready and coached by recognized industry experts.”
The program will kick-off with intensive mentoring by CONNECT's world renown Springboard mentoring program that will help the company fine-tune its investor pitch before it presents to industry judges to vie for the opportunity to present to a series of investor showcases for angels, venture capital firms, corporate venture and licensing representatives and family foundations across California.
By participating in the program, Kalos will have also have access to networking with prominent connections in the industry, entrepreneur clinics and a collaborative workspace, provided by CONNECT.
Kalos Therapeutics George Colberg, Executive Chairman 858-552-6890
Kalos Therapeutics, Inc.
For further information contact email@example.com or 858-552-6890
CONTACT: Kalos Therapeutics George Colberg, Executive Chairman 858-552-6890
North America, California
INDUSTRY KEYWORD: Cancer, Health, Biotechnology, Novel Therapies, Oncology, ARMD, Pharmaceutical, Research